Latest News on Pfizer Inc. (PFE) Stock

  • Traders Watch List -Pfizer Inc. (NYSE:PFE) United States Steel Corp. (NYSE:X ... [September 1 2015 02:31 AM]
  • Traders Watch List -Pfizer Inc. (NYSE:PFE) United States Steel Corp. (NYSE:X ...   wsnewspublishers - 6 hours ago Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) declared that 22 abstracts (late-breaking, rapid-fire, oral and poster presentations) will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. Pfizer, Inc. (NYSE:PFE) Give... Read more about this Pfizer Inc. (PFE) news
  • Why Pfizer Inc. Should Feel Threatened By Roche Holding Ltd. (ADR) [September 1 2015 02:11 AM]
  • Why Pfizer Inc. Should Feel Threatened By Roche Holding Ltd. (ADR)   Bidness ETC - 6 hours ago In fiscal year 2011 (FY11), its revenues fell by 2.7% year-over-year (YoY), followed by an even higher decline of 16.2% in FY12. The company expects to be on track towards revenue growth again from 2016. Pfizer anticipates revenue gains of 12.8% YoY in ... Read more about this Pfizer Inc. (PFE) news


  • Large Inflow of Money Witnessed in Pfizer, Inc. [August 31 2015 11:22 PM]
  • Large Inflow of Money Witnessed in Pfizer, Inc.   Money Flow Index - 9 hours ago Pfizer, Inc. (NYSE:PFE) traded with a cut of -0.44 points or -1.35% at $32.22 per share. As per the last available information, the stock aggregated $220.66 million in upticks and $106.25 million in downticks, keeping the net money flow capped at $114 ... Read more about this Pfizer Inc. (PFE) news


  • Pfizer Inc. (PFE) Closes 1.35% Down on the Day for August 31 [August 31 2015 01:59 PM]
  • Pfizer Inc. (PFE) Closes 1.35% Down on the Day for August 31   Equities.com - 19 hours ago Dow Jones component Pfizer Inc. (PFE) saw its stock move -1.35% to $32.22, representing a per-share move of $0.44, on volume of 31.9 million shares for Monday. Should You Sell GE, AT&T, Pfizer? Check Weekly Charts - Nasdaq  Read more about this Pfizer Inc. (PFE) news
  • Europe gets Amgen cholesterol drug for 50-60 pct of U.S. price [September 1 2015 06:00 AM]
  • [Reuters] - Amgen is launching its injectable cholesterol drug in Europe at around half the U.S. price, in a move likely to stoke controversy about the way Americans end up paying far more than others for new medicines. Repatha belongs to a potent and expensive new class of drugs for lowering "bad" LDL cholesterol, whose high cost has prompted concerns among healthcare providers and doctors. Read more about this Pfizer Inc. (PFE) news

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center